Marie Thibault
Stock Analyst at BTIG
(0.03)
# 4,344
Out of 4,352 analysts
768
Total ratings
33.6%
Success rate
-14.5%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Rated: Buy | $260 → $235 | $144.94 | +62.14% | 49 | May 27, 2026 | |
| DXCM DexCom | Reiterated: Buy | $80 | $73.74 | +8.49% | 53 | May 15, 2026 | |
| HYPR Hyperfine | Reiterated: Buy | $2 | $1.56 | +28.21% | 2 | May 13, 2026 | |
| CBLL CeriBell | Reiterated: Buy | $30 → $28 | $18.45 | +51.76% | 11 | May 12, 2026 | |
| ARAY Accuray | Downgraded: Hold | n/a | $0.3784 | - | 38 | May 7, 2026 | |
| IRTC iRhythm Holdings | Maintained: Buy | $185 | $113.90 | +62.42% | 58 | May 7, 2026 | |
| ATRC AtriCure | Reiterated: Buy | $54 → $45 | $27.67 | +62.63% | 50 | May 6, 2026 | |
| EMBC Embecta | Downgraded: Hold | n/a | $3.38 | - | 27 | May 6, 2026 | |
| EW Edwards Lifesciences | Reiterated: Buy | $103 → $100 | $86.47 | +15.65% | 40 | Apr 24, 2026 | |
| BSX Boston Scientific | Maintained: Buy | $110 → $80 | $48.31 | +65.60% | 74 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $131 | $85.60 | +53.04% | 52 | Apr 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $88 → $84 | $67.81 | +23.88% | 11 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $30 | $21.26 | +41.11% | 7 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $12.04 | +107.64% | 1 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.46 | - | 15 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $6.79 | - | 37 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $10.78 | +113.36% | 29 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $178.45 | - | 70 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.91 | - | 8 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $4.89 | +206.75% | 18 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $70.69 | n/a | 55 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $312.06 | n/a | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $318.30 | n/a | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 37 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $89 | $73.81 | n/a | 1 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.54 | n/a | 23 | Dec 16, 2022 |
Insulet
May 27, 2026
Rated: Buy
Price Target: $260 → $235
Current: $144.94
Upside: +62.14%
DexCom
May 15, 2026
Reiterated: Buy
Price Target: $80
Current: $73.74
Upside: +8.49%
Hyperfine
May 13, 2026
Reiterated: Buy
Price Target: $2
Current: $1.56
Upside: +28.21%
CeriBell
May 12, 2026
Reiterated: Buy
Price Target: $30 → $28
Current: $18.45
Upside: +51.76%
Accuray
May 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.3784
Upside: -
iRhythm Holdings
May 7, 2026
Maintained: Buy
Price Target: $185
Current: $113.90
Upside: +62.42%
AtriCure
May 6, 2026
Reiterated: Buy
Price Target: $54 → $45
Current: $27.67
Upside: +62.63%
Embecta
May 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.38
Upside: -
Edwards Lifesciences
Apr 24, 2026
Reiterated: Buy
Price Target: $103 → $100
Current: $86.47
Upside: +15.65%
Boston Scientific
Apr 22, 2026
Maintained: Buy
Price Target: $110 → $80
Current: $48.31
Upside: +65.60%
Apr 17, 2026
Maintained: Buy
Price Target: $131
Current: $85.60
Upside: +53.04%
Apr 13, 2026
Maintained: Buy
Price Target: $88 → $84
Current: $67.81
Upside: +23.88%
Apr 13, 2026
Maintained: Buy
Price Target: $32 → $30
Current: $21.26
Upside: +41.11%
Mar 31, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $12.04
Upside: +107.64%
Mar 26, 2026
Maintained: Hold
Price Target: n/a
Current: $0.46
Upside: -
Mar 3, 2026
Maintained: Hold
Price Target: n/a
Current: $6.79
Upside: -
Feb 18, 2026
Maintained: Buy
Price Target: $23
Current: $10.78
Upside: +113.36%
Feb 18, 2026
Downgraded: Hold
Price Target: n/a
Current: $178.45
Upside: -
Feb 18, 2026
Maintained: Hold
Price Target: n/a
Current: $3.91
Upside: -
Feb 18, 2026
Maintained: Buy
Price Target: $15
Current: $4.89
Upside: +206.75%
Apr 10, 2025
Reiterated: Buy
Price Target: $62
Current: $70.69
Upside: n/a
Oct 27, 2023
Reiterated: Buy
Price Target: $150
Current: $312.06
Upside: n/a
Jul 26, 2023
Rated: Buy
Price Target: n/a
Current: $318.30
Upside: n/a
Jul 17, 2023
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Feb 21, 2023
Rated: Hold
Price Target: $89
Current: $73.81
Upside: n/a
Dec 16, 2022
Rated: Hold
Price Target: n/a
Current: $1.54
Upside: n/a